EDIT - Can This Beaten-Down Stock Bounce Back?
2025-08-12 10:00:00 ET
Editas Medicine (NASDAQ: EDIT) , a small-cap biotech company, is up by 81% since January. But zooming out gives us a completely different picture. The gene-editing specialist has significantly lagged the market over the past year -- and since the turn of the decade, for that matter; it's down more than 90% since 2020.
Its upward trend in 2025 may attract investors who might see even more potential upside for a stock whose shares still trade below $3 apiece. Before you get on the bandwagon, though, it's essential to figure out whether Editas can maintain this momentum over the long run.
Image source: Getty Images.